The combination of low-dose bufadienolides and tamoxifen could significantly enhance the inhibitory effect of tamoxifen on HER2 overexpression breast cancer cells, which suggested that ABG and BF might be potential adjuvant therapy drugs for the treatment of HER2 overexpression breast cancer [30]. This evidence concerns the gene ERBB2 and breast cancer.